373 related articles for article (PubMed ID: 10619466)
21. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Buck K; Ferger B
Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
23. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum.
Lopez A; Muñoz A; Guerra MJ; Labandeira-Garcia JL
Neuroscience; 2001; 103(3):639-51. PubMed ID: 11274784
[TBL] [Abstract][Full Text] [Related]
25. Dual effects of L-DOPA on nigral dopaminergic neurons.
Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
[TBL] [Abstract][Full Text] [Related]
26. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
27. The effect of reserpine treatment in vivo upon L-dopa and amphetamine evoked dopamine and DOPAC efflux in vitro from the corpus striatum of male rats.
Dluzen DE; Liu B
J Neural Transm Gen Sect; 1994; 95(3):209-22. PubMed ID: 7865176
[TBL] [Abstract][Full Text] [Related]
28. L-DOPA inhibits depolarization-induced [3H]GABA release in the dopamine-denervated globus pallidus of the rat: the effect is dopamine independent and mediated by D2-like receptors.
Silva I; Cortes H; Escartín E; Rangel C; Florán L; Erlij D; Aceves J; Florán B
J Neural Transm (Vienna); 2006 Dec; 113(12):1847-53. PubMed ID: 16736236
[TBL] [Abstract][Full Text] [Related]
29. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
Nakazato T; Akiyama A
Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
[TBL] [Abstract][Full Text] [Related]
30. Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.
Haase AF; Greiner HE; Seyfried CA
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jun; 343(6):588-94. PubMed ID: 1682817
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat.
Fisher A; Biggs CS; Starr MS
Brain Res; 1998 May; 792(1):126-32. PubMed ID: 9593857
[TBL] [Abstract][Full Text] [Related]
32. Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists.
Zhu MY; Juorio AV; Paterson IA; Boulton AA
Br J Pharmacol; 1994 May; 112(1):23-30. PubMed ID: 7913379
[TBL] [Abstract][Full Text] [Related]
33. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Jonkers N; Sarre S; Ebinger G; Michotte Y
J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
[TBL] [Abstract][Full Text] [Related]
34. Biphasic actions of L-DOPA on the release of endogenous noradrenaline and dopamine from rat hypothalamic slices.
Goshima Y; Kubo T; Misu Y
Br J Pharmacol; 1986 Sep; 89(1):229-34. PubMed ID: 3801773
[TBL] [Abstract][Full Text] [Related]
35. Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: neurochemical effects.
Kaddis FG; Clarkson ED; Weber MJ; Vandenbergh DJ; Donovan DM; Mallet J; Horellou P; Uhl GR; Freed CR
J Neurochem; 1997 Apr; 68(4):1520-6. PubMed ID: 9084422
[TBL] [Abstract][Full Text] [Related]
36. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
Jackson D; Abercrombie ED; Zigmond MJ
J Pharmacol Exp Ther; 1993 Nov; 267(2):912-8. PubMed ID: 8246167
[TBL] [Abstract][Full Text] [Related]
37. Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain.
Strömbom U
Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(2):167-76. PubMed ID: 181681
[TBL] [Abstract][Full Text] [Related]
38. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
Matsushita N; Misu Y; Goshima Y
Eur J Pharmacol; 2009 Mar; 605(1-3):109-13. PubMed ID: 19168057
[TBL] [Abstract][Full Text] [Related]
39. NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors.
Nissbrandt H; Engberg G; Wikström H; Magnusson T; Carlsson A
Naunyn Schmiedebergs Arch Pharmacol; 1988 Aug; 338(2):148-61. PubMed ID: 3141816
[TBL] [Abstract][Full Text] [Related]
40. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
